| Document |
Document Title |
|
WO/2024/017318A1 |
The present application belongs to the technical field of microorganisms and provides Ralstonia eutropha having low endotoxin content and a use thereof. Further provided is a use of the reduction of enzymatic activity and/or expression o...
|
|
WO/2024/018452A1 |
An albumin protein is provided. The albumin protein is soluble when expressed in bacteria and characterized by increased thermostability as compared to wild type human serum albumin (HSA). Also provided are nucleic acid molecules encodin...
|
|
WO/2024/019489A1 |
The present invention relates to an AAV vector and cell-penetrating peptide fusion platform and a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, including same. The platform overcomes the limit...
|
|
WO/2024/018061A1 |
Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 stain could modulate ...
|
|
WO/2024/017479A1 |
Disclosed herein is a multifunctional cell recombinantly expressing an immune receptor and two or more cytokines, wherein the cell comprises one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines. ...
|
|
WO/2024/019553A1 |
The present invention relates to: a method for increasing the half-life of a botulinum toxin type A light chain (AUT-BT-LC) protein, the method comprising substituting one or more lysine residues present in the amino acid sequence of the...
|
|
WO/2024/016762A1 |
Provided in the present invention are a galectin 10 (Gal10) crystal, and an antibody IgY and a pharmaceutical preparation prepared thereby, which belong to the technical field of medicine. In the present invention, a yolk neutralizing an...
|
|
WO/2023/172916A9 |
Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 ("a GPC-CAR"); and (b) an orthogonal receptor. Also provided are methods of making and using s...
|
|
WO/2024/018369A1 |
The present invention is directed to compositions of novel, non-naturally occurring IL-12 variants, homodimeric IL-12 Fc fusion proteins, and heterodimeric IL-12 Fc fusion proteins, as well as methods of making and using such compositions.
|
|
WO/2024/015428A1 |
The disclosure elates generally to methods and compositions for generation or enhancement of partial or complete cellular signaling pathways.
|
|
WO/2024/015822A1 |
Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
|
|
WO/2024/015724A1 |
A ribonucleic acid comprising two non-natural pre-miRNA sequences, wherein each pre-miRNA sequence comprises a guide miRNA that inhibits the expression of an immune checkpoint protein. The pre-miRNA sequences may target a different gene ...
|
|
WO/2024/015611A2 |
The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing th...
|
|
WO/2024/015995A2 |
The present technology provides chimeric antigen receptors (CARs) comprising a TMIGD2 costimulatory domain. In certain embodiments, these CARs comprise an intracellular region comprising the TMIGD2 costimulatory domain and an effector do...
|
|
WO/2024/015960A1 |
The present disclosure relates to cleavable carriers and cleavable carrier-linked cytokine prodrugs wherein the cleavable carrier is an engineered Fc domain comprising at least one tumor-associated protease cleavage site. Upon cleavage a...
|
|
WO/2024/014894A1 |
The present invention relates to an extracellular vesicle comprising an antigenic protein or a gene encoding the antigenic protein and uses thereof and, more specifically, to an extracellular vesicle comprising an antigenic protein deriv...
|
|
WO/2024/015797A1 |
The present disclosure relates to peptide having a sequence comprising: Z1X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15-NH2 (SEQ ID NO: 1), And to their isomers, pharmaceutically acceptable salts, or prodrugs thereof, methods of use, and methods ...
|
|
WO/2024/015362A1 |
This disclosure provides fluorescent proteins that withstand chaotropic conditions that denature most biological structures within seconds, including superfolder GFP. The disclosed fluorescent proteins contain no cysteines, is chloride i...
|
|
WO/2024/015853A2 |
Disclosed herein are fusion proteins comprising the CR3 domain of the low density lipoprotein (LDLR) and a polypeptide with phase behavior. Also provided herein are polypeptides with phase behavior. Additionally provided herein are metho...
|
|
WO/2024/015872A2 |
The present disclosure provides engineered antigen compositions that reduce immune response to the antigen in a subject having an immune response to the antigen. The present disclosure also provides pharmaceutical compositions that inclu...
|
|
WO/2024/014560A1 |
Provided are: an expression vector into which a gene encoding parasporin (hereinafter, referred to as "PS") is inserted and with which a pharmaceutical composition applicable to the treatment of cancer can be achieved; a cell into which ...
|
|
WO/2024/014808A1 |
The present invention relates to a cytokine fusion protein comprising an immune cell targeting domain and a cytokine action domain that can specifically induce the proliferation and/or activation of immune cells. Specifically, the presen...
|
|
WO/2024/014463A1 |
The present invention provides a drug for suppressing the growth of kidney stones, the drug containing a peptide that includes an amino acid sequence satisfying the following conditions or a nucleic acid that encodes said peptide: (1) Am...
|
|
WO/2024/015988A1 |
In general, the present disclosure relates to the discovery that T cells expressing IL-9R are more efficacious against cancer when administered in combination with the IL-9 cytokine. The combination can allow for the T cells to effect an...
|
|
WO/2024/015734A1 |
Provided are recombinant cytokine receptors that comprise an IL-2 intracellular domain and an extracellular domain that binds to a cytokine other than IL-2. Also provided herein are Treg cell comprising recombinant cytokine receptors and...
|
|
WO/2024/013487A1 |
Provided herein are methods and compositions for the on-device detection of protein synthesis using fluorescent proteins. The methods are applicable to monitoring on a microfluidic device.
|
|
WO/2024/012420A1 |
Disclosed are a universal cell for expressing FASLG, and a preparation method therefor and the use thereof. By means of inactivating major histocompatibility complex (MHC) class I and II genes in cells and overexpressing the FASLG protei...
|
|
WO/2024/015966A2 |
Novel AAV capsids and recombinant AAV vectors comprising the same are provided.
|
|
WO/2022/251585A9 |
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Plasmodium parasitic antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administerin...
|
|
WO/2024/016003A2 |
An engineered AAV capsid is provided, in which at least one protein on the capsid is modified to include a n-mer motif, which promotes transduction of the capsid into the central nervous system (CNS) through interaction with the Transfer...
|
|
WO/2024/013401A1 |
A novel method for identifying γT-cell (or delta T-cell) receptor chains (or γδTCRs) or fragments thereof that mediate an anti-tumour or an anti-infective response, and novel γT-cell receptor chains, δT-cell receptor chains, γδTCR...
|
|
WO/2024/015257A1 |
This document relates to methods and materials for promoting bone growth. For example, one or more inhibitors of an embryonic ectoderm development (EED) polypeptide can be administered to a mammal (e.g., a human) to promote bone growth w...
|
|
WO/2024/014426A1 |
The present invention addresses the problem of clarifying the true cause of interstitial pneumonia that is associated with myositis/dermatomyositis to thereby enable a more accurate diagnosis of the onset risk of interstitial pneumonia a...
|
|
WO/2024/011333A1 |
There is provided a method of preventing or treating muscular dystrophy in a subject in need thereof comprising administering a therapeutically effective amount of a stimulator of muscle stem cell (MuSC) function to the subject.
|
|
WO/2024/015862A1 |
The present disclosure relates generally to the field of immunology, and particularly relates to methods for the identification and/or characterization of target specific antigen-binding molecules (e.g., antibodies) produced by immune ce...
|
|
WO/2024/012423A1 |
Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and/or treating hepatiti...
|
|
WO/2024/015366A1 |
The present invention is related to compositions and methods that reduce methane production in ruminant populations.
|
|
WO/2024/015047A1 |
The current disclosure provides methods for the production of 'vaccine-like' antiviral preparations. The present disclosure provides compounds for the treatment of a wide range of enveloped viral diseases and conditions. The present disc...
|
|
WO/2024/015958A1 |
The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimm...
|
|
WO/2024/012487A1 |
Provided is a protein including a polypeptide having at least 95%sequence homology with an amino acid sequence selected from a group consisting of SEQ ID NOs: 1 to 5, where the amino acid at position 70 of SEQ ID NOs: 1-5 must be cystein...
|
|
WO/2024/015981A2 |
An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them.
|
|
WO/2024/015974A1 |
A phospholipase A1 characterized by having an sn1/sn2 specificity ratio of about 55/45 or greater wherein said phospholipase A1 has a lysophospholipase/phospholipase activity ratio of less than 0.01 is presented in conjunction with metho...
|
|
WO/2024/015722A2 |
FRET-based fusion protein biosensors and methods for their use in measuring an NAD+/NADH ratio change in live cells are provided.
|
|
WO/2024/015678A1 |
Disclosed are methods of treating cancer in a subject comprising (i) administering a pharmaceutical composition comprising a therapeutically effective amount of a mutagenized IL13 moiety (mIL13); and then (ii) delivering a radiation ther...
|
|
WO/2024/015881A2 |
Provided in some aspects are transcriptional activation domains for targeted transcriptional activation. Also provided are multipartite effectors, fusion proteins, and DNA-targeting systems, such as CRISPR/Cas-based DNA-targeting systems...
|
|
WO/2024/013402A1 |
Novel soluble γT-cell receptor chains, soluble δT-cell receptor chains, soluble γδTCRs, or fragments thereof, mediating anti-tumour responses or anti-infective responses are provided.
|
|
WO/2024/015723A1 |
Engineered tunable chimeric receptor/ligand pairs, and methods of use thereof, are provided.
|
|
WO/2024/013381A1 |
The invention relates to a method of detecting an interaction or proximity between a fusion protein and a target protein. The method may comprise a) providing a fusion protein and/or a recombinant nucleic acid molecule encoding said fusi...
|
|
WO/2024/015877A2 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these cap...
|
|
WO/2024/013727A1 |
Antigen-binding molecules that are engineered to replace the light chain constant domain (CL) and heavy chain constant domain 1 (CH1) with HLA class I histocompatibility antigen alpha chain-E alpha-3 (HLA-E)/Beta-2 microglobulin (B2M) or...
|
